uploads///Graph

JNJ’s Consumer Business: International Market Trends in Q1

By

Updated

OTC business performance in international markets

In the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported a 3% YoY (year-over-year) rise in ex-US sales. According to the company’s first-quarter earnings conference call, this performance was mainly driven by the solid uptake of Rhinocort for allergies, Nicorette QuickMist for smoking cessation, and Motrin in the pediatric analgesics market—especially in Asia. The company, however, suffered a setback in upper respiratory brand sales because of shorter cough, cold, and flu seasons in Russia and North America.

Article continues below advertisement

Baby care business

In the first quarter, Johnson & Johnson’s (JNJ) baby care business, a part of its Consumer segment, reported worldwide sales of $394 million, reflecting YoY falls of 14.0% on a reported basis and 7.4% on an operational basis. According to the company’s first-quarter earnings investor presentation, its Johnson’s Baby brand reported a channel shift to the Aveeno brand in the US market against a backdrop of reducing exports and overall market softness. Additionally, retail destocking in Southeast Asia and Europe, the Middle East, and Africa ahead of the Johnson’s Baby brand’s relaunch in ex-US markets also affected the company’s baby care business’s revenue. In the first quarter, the Johnson’s Baby brand reported growth in three out of four key newly relaunched markets: India, China, and Canada.

Women’s health business

In the first quarter, Johnson & Johnson’s women’s health business, a part of its Consumer segment, reported worldwide sales of $225 million, a YoY rise of 4.3% on an operational basis but a fall of 7.3% on a reported basis. According to the company’s first-quarter earnings investor presentation, this performance was attributable to an increase in sanitary napkin offerings (in terms of sizes and counts) in the Indian market.

Advertisement

More From Market Realist